CoGenesis® Cancer

Pan-cancer treatment selection test

Our technology offers comprehensive genomic profiling of tumors. Together with clinicians, we use a robust pharmacogenomics database to harness the information needed for accurate diagnosis in just 4 weeks. This allows for tailored and targeted therapy and immunotherapy suggestions, reducing potential side effects and shortening recovery time.
Contact For More Information

About CoGenesis® Cancer

Thousands can benefit

Our testing is designed for cancer patients who are not responding to conventional cancer therapies and patients looking for personalised therapies based on their genetic profiles. We provide the information needed about the molecular subtypes of a patient’s tumour.

Changing our understanding

Traditionally, cancers have been classified by the location of tumours within the body, with underlying DNA mutations overlooked. Research shows that the same set of DNA mutations can cause multiple cancer types, and when these are identified, more effective treatments can be selected based on an individual’s genetic profile.
Comprehensive DNA & RNA sequencing of


cancer-related genes
Specific markers for


major cancer types
Covering up to


FDA-approved or experimental targeted therapies

The process


A tumor or a blood biopsy sample is taken.


The sample then undergoes targeted next-generation sequencing.


Mutations are identified and confirmed by complimentary technologies.


Evidence-based targeted treatments are recommended.

Technical Specification

Targeted cancer therapy can improve overall lung cancer survival rates up to 8 times.

A high accuracy standard

Steps Accuracy
DNA sequencing 99.9%
Variant calling – SNP >99%*#
Variant calling – Indel >99%*#

* Passed GenQA/UK NEQAS external quality assurance

# The interpretation of sequencing variants is based on the current understanding of the variants at the time it was observed, which may change over time as more information about the genes becomes available. Not all variants are represented in this report.